Two phase II trials of temozolomide with interferon-|[alpha]|2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme

M D Groves; V K Puduvalli; M R Gilbert; V A Levin; C A Conrad; V H Liu; K Hunter; C Meyers; K R Hess; W K Alfred Yung

首页> 外文期刊>British Journal of Cancer >Two phase II trials of temozolomide with interferon-|[alpha]|2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme

【24h】

Two phase II trials of temozolomide with interferon-|[alpha]|2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme

机译：替莫唑胺与干扰素-|α| 2b（聚乙二醇化和非聚乙二醇化）在复发性多形性胶质母细胞瘤患者中的两项II期试验

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background:Because of the poor outcomes for patients with recurrent glioblastoma multiforme (GBM), and some laboratory and clinical evidence of efficacy using interferon in GBM, we assessed the toxicity and efficacy of temozolomide (TMZ) combined with either short-acting (IFN) or long-acting (pegylated) interferon α2b (PEG) in two single-arm phase II studies, and compared the results to 6-month progression-free survival (PFS-6) data from historical controls.

机译：背景：由于复发性多形性胶质母细胞瘤（GBM）患者的预后较差，以及在GBM中使用干扰素的疗效的一些实验室和临床证据，我们评估了替莫唑胺（TMZ）结合短效（IFN）的毒性和疗效或两项单臂II期研究中的长效（聚乙二醇化）干扰素α2b（PEG），并将结果与历史对照组的6个月无进展生存期（PFS-6）数据进行了比较。

著录项

来源
《British Journal of Cancer》 |2009年第4期|共6页
作者
M D Groves; V K Puduvalli; M R Gilbert; V A Levin; C A Conrad; V H Liu; K Hunter; C Meyers; K R Hess; W K Alfred Yung;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. [J] . Ananda S, Nowak AK, Cher L, Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia . 2011,第11期

机译：替莫唑胺和聚乙二醇化脂质体阿霉素在同时放疗和化疗后治疗多形性胶质母细胞瘤患者的2期试验。
2. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. [J] . Groves MD, Puduvalli VK, Chang SM, Journal of neuro-oncology. . 2007,第3期

机译：替莫唑胺加沙利度胺用于复发性多形性胶质母细胞瘤的北美脑肿瘤联盟（NABTC 99-04）II期试验。
3. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme [J] . Morris D. Groves, Vinay K. Puduvalli, Susan M. Chang, Journal of Neuro-Oncology . 2007,第3期

机译：替莫唑胺+沙利度胺治疗复发性多形性胶质母细胞瘤的北美脑肿瘤联盟（NABTC 99-04）II期试验
4. Glioblastoma multiforme treated by the chemotherapeutic agent temozolomide in vivo: a 4D simulation model of the tumor response [C] . V.P. Antipas, G.S. Stamatakos, N.K. Uzunoglu . 2005

机译：替莫唑胺在体内治疗多形性胶质母细胞瘤：肿瘤反应的4D模拟模型
5. Overcoming Temozolomide Resistance in Glioblastoma Multiforme with MGMT-Targeting Spherical Nucleic Acids. [D] . Sita, Timothy L. 2017

机译：MGMG靶向球形核酸克服胶质母细胞瘤中替莫唑胺的耐药性。
6. Two phase II trials of temozolomide with interferon-α2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme [O] . M D Groves, V K Puduvalli, M R Gilbert, 2009

机译：替莫唑胺与干扰素-α2b（聚乙二醇化和非聚乙二醇化）在复发性多形性胶质母细胞瘤患者中的两项II期试验
7. Two phase II trials of temozolomide with interferon-α2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme [O] . Groves, M D, Puduvalli, V K, Gilbert, M R, 2009

机译：替莫唑胺与干扰素-α2b（聚乙二醇化和非聚乙二醇化）在复发性多形性胶质母细胞瘤患者中的两项II期试验

Two phase II trials of temozolomide with interferon-|[alpha]|2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme

摘要

著录项

相似文献

相关主题

期刊订阅